Welcome to our dedicated page for Gt Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on Gt Biopharma stock.
GT Biopharma Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company developing cancer therapeutics based on its proprietary TriKE natural killer (NK) cell engager platform. The GTBP news feed on Stock Titan aggregates company press releases, clinical updates, financial disclosures, and other public announcements so readers can follow how its NK cell–based programs progress over time.
News about GT Biopharma frequently centers on its lead clinical candidate GTB-3650, a second-generation TriKE being evaluated in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, including acute myeloid leukemia and high-risk myelodysplastic syndrome. Regular updates describe enrollment status across multiple cohorts, results of formal safety reviews, early observations on immune activation and NK cell expansion, and plans for subsequent dose levels within the study protocol.
Another recurring theme in GTBP news is the advancement of GTB-5550, a camelid nanobody-based TriKE targeting B7-H3–expressing solid tumors. Company announcements cover key regulatory milestones such as submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration and outline the design of a planned Phase 1 basket trial using subcutaneous dosing across several metastatic solid tumor cohorts.
Investors and observers will also find financial result releases, which summarize cash position, research and development spending related to GTB-3650 and GTB-5550, and general operating expenses, along with 8-K-linked updates on Nasdaq listing matters and capital structure changes. Conference participation notices and board or governance updates provide additional context on how GT Biopharma presents its NK cell engager strategy to the investment community.
By reviewing GTBP news on this page, readers can track clinical milestones, regulatory interactions, financing developments, and corporate actions that shape the company’s progress in NK cell–based immuno-oncology.
GT Biopharma has appointed Dr. Greg Berk, M.D. to its Board of Directors. Dr. Berk brings extensive experience in oncology drug development, having previously held senior positions at Verastem, Sideris Pharmaceuticals, and BIND Therapeutics. He is expected to contribute significantly to the advancement of the company's proprietary NK cell engager (TriKE™) technology, particularly in developing its lead candidate, GTB-3550, for treating acute myeloid leukemia (AML). GT Biopharma aims to harness the immune system to combat cancer effectively.
GT Biopharma has appointed Michael Handelman, CPA, as its new Chief Financial Officer. Mr. Handelman has an extensive background, previously serving as CFO for Iovance Biotherapeutics and Clickstream Corporation. His expertise in financial management within the biotech sector is expected to enhance GT Biopharma's operational and clinical development of its NK cell engager technology, TriKE™. The company focuses on innovative cancer therapies, particularly its GTB-3550 candidate aimed at treating acute myeloid leukemia (AML) and related conditions.
GT Biopharma has announced that its abstract, titled "GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts", has been selected for oral presentation at the 62nd ASH Annual Meeting on December 5, 2020. Interim data from 7 enrolled patients showed promising NK cell activity without serious adverse events. The drug aims to offer therapy for patients lacking actionable mutations, with plans for further clinical evaluation to demonstrate potential efficacy.
GT Biopharma, Inc. (OTCQB:GTBP) announced that its abstract regarding GTB-3550 TriKE for treating high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been selected for oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting on December 5, 2020. The abstract highlights NK cell proliferation at initial dose cohorts. The results will also be published in the November supplemental issue of the journal Blood. GTB-3550 is currently under evaluation in a Phase I/II clinical trial targeting CD33 positive leukemias.
GT Biopharma announced the addition of Dr. Samir Taneja and Dr. Philip Werthman to its Scientific and Medical Advisory Board. Dr. Taneja, a urologic oncology expert from NYU, brings extensive knowledge in cancer treatment. Dr. Werthman, noted for his contributions in reproductive medicine, offers valuable experience in translating research into commercial success. CEO Anthony Cataldo expressed optimism about how their expertise will enhance GT Biopharma's mission to expand its TriKE technology applications.
GT Biopharma has entered a partnership with Cytovance Biologics for exclusive GMP manufacturing of three TriKETM therapeutic candidates. The deal allows for a $6 million payment in cash or shares, contingent on milestone achievements within 12 months. Cytovance's KeystoneTM systems promise enhanced production yields. GT Biopharma's TriKETM platform targets NK cell engagement to treat cancers, with its first product candidate, GTB-3550, in Phase I/II trials for AML. This partnership highlights GT Biopharma's commitment to expanding clinical opportunities.
GT Biopharma announced the treatment completion of its first patient in the GTB-3550 TriKE Phase I/II clinical trial, achieving a reduction in acute myeloid leukemia (AML) blast levels from 18% to 12%. The patient displayed enhanced NK cell activity, attributed to the IL-15 component, without adverse reactions. This trial aims to evaluate the safety, tolerability, and efficacy of GTB-3550 in high-risk hematologic malignancies. The company expresses hope for continued positive outcomes as it escalates dosing in future treatments.